logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
12/1/2017 12:23:14 PM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $70 Price Target
11/6/2017 8:38:11 AM Aimmune Therapeutics Q3 Loss/shr Widens To $0.63 From $0.53 Last Year; CEO Stephen Dilly To Retire By End Of 2018
10/31/2017 8:43:39 AM Aimmune Therapeutics Announces Online Publication Of Positive Data From Its ARC001 Phase 2 Clinical Trial Of AR101
10/23/2017 9:32:53 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $70 Up From $42 Price Target
10/16/2017 7:37:13 AM Aimmune Announces Clinical Collaboration To Study AR101 With Regeneron And Sanofi’s Dupilumab For Peanut Allergy
8/14/2017 9:49:20 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Ourperform With $42 Price Target
7/24/2017 8:00:24 PM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $42.00 Price Target
7/5/2017 8:06:04 AM Aimmune Enrolls First Patient In ARTEMIS European Phase 3 Trial Of AR101 For Treatment Of Peanut Allergy
6/20/2017 6:31:49 AM Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data At 2017 EAACI Congress
6/14/2017 6:41:36 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Ourperform With $42 Price Target
5/9/2017 11:48:40 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At outperform With $42 Price Target
5/9/2017 11:47:54 AM Wedbush Is Increasing Aimmune Therapeutics Inc. (AIMT) 2017 Estimate To -2.61 From -2.71
5/9/2017 11:47:38 AM Wedbush Is Increasing Aimmune Therapeutics Inc. (AIMT) 4Q17 Estimate To -0.80 From -0.82
5/9/2017 11:47:21 AM Wedbush Is Raising Aimmune Therapeutics Inc. (AIMT) 3Q17 Estimate To -0.69 From -0.71
5/9/2017 11:47:00 AM Wedbush Is Increasing Aimmune Therapeutics Inc. (AIMT) 2Q17 Estimate To -0.60 From -0.63
4/13/2017 6:01:08 AM Aimmune Therapeutics Appoints Eric Bjerkholt As CFO